Eosinophilic Endomyocarditis After COVID-19 Infection in a Heart Transplant Recipient

Sara S Inglis,Anshul R Gupta,Francisco B Alexandrino,Marie C Aubry,Leslie T Cooper,Nandan S Anavekar,Atta Behfar,Shannon M Dunlay,Jacob C Jentzer,Adrian daSilva-deAbreu
DOI: https://doi.org/10.1016/j.jaccas.2024.102527
2024-09-18
Abstract:Eosinophilic myocarditis (EM) is a rare cause of heart failure, with high in-hospital mortality associated with fulminant disease. A 61-year-old female transplant recipient was diagnosed with COVID-19 after presenting with 2 days of constitutional symptoms. She developed acute heart failure from EM. After an initial response to inotropic support and corticosteroids, she had a relapse with de novo peripheral eosinophilia which responded to further eosinophilic myocarditis management and the addition of mepolizumab. Although there have been reports after COVID-19 vaccination, association with active SARS-CoV-2 infection is rare. This paper reports, for the first time, the case of a heart transplant recipient with EM after COVID-19.
What problem does this paper attempt to address?